Expertise in
9
conditions

Dr. Elber S. Camacho

Hematology
Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, 
Palm Springs, CA 
Expertise in
9
conditions
Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, 
Palm Springs, CA 

Overview

Elber Camacho is a Hematologist practicing medicine in Palm Springs, California.

Dr. Camacho is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia (CLL).

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, Palm Springs, CA 92262

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
Enrollment Status: Completed
Publish Date: July 03, 2023
View 7 Less Clinical Trials

3 Total Publications

An unusual case of primary acinar cell carcinoma of the liver and its treatment.
An unusual case of primary acinar cell carcinoma of the liver and its treatment.
Journal: Journal of gastrointestinal oncology
Published: October 12, 2019
Similar Doctors
Expertise in
59
conditions
Expertise in
59
conditions
Referral may be required

Eisenhower Health

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (11.5 miles away)
760-346-7655
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Henry Tsai is a Hematologist practicing medicine in Rancho Mirage, California. Dr. Tsai is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Agranulocytosis, Febrile Neutropenia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Advanced Bronchoscopy.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Loma Linda Univ Anesthesiology Medical Group Inc

11234 Anderson St, 
Loma Linda, CA 
 (42.1 miles away)
909-558-4910
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mojtaba Akhtari is a Hematologist practicing medicine in Loma Linda, California. Dr. Akhtari is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Hematology/Oncology Consultants

301 N San Jacinto St, 
Hemet, CA 
 (23.8 miles away)
951-766-6460
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Evelyn Mendoza is a Hematologist practicing medicine in Hemet, California. Dr. Mendoza is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Vitamin B12 Deficiency, Agranulocytosis, Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Elber S. Camacho

How do I make an appointment with Dr. Elber S. Camacho?

You can book an appointment with Dr. Elber S. Camacho by calling their office at 760-416-4880. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elber S. Camacho a top-rated expert for Essential Thrombocythemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elber S. Camacho is classified as an Advanced expert for Essential Thrombocythemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elber S. Camacho specialize in?

While Dr. Elber S. Camacho is a Hematology, they have specific expertise in Essential Thrombocythemia, Hodgkin Lymphoma, and Classical Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Elber S. Camacho participate in research or clinical trials?

Yes. Dr. Elber S. Camacho has published 3 articles and abstracts on conditions like Essential Thrombocythemia. You can view a list of Dr. Elber S. Camacho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elber S. Camacho accept my insurance?

Dr. Elber S. Camacho accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 760-416-4880 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Camacho's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 40 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile